Pharmacodynamic profile of Zaleplon, a new non‐benzodiazepine hypnotic agent

@article{Patat2001PharmacodynamicPO,
  title={Pharmacodynamic profile of Zaleplon, a new non‐benzodiazepine hypnotic agent},
  author={Alain A. Patat and Isabelle Paty and Ian Hindmarch},
  journal={Human Psychopharmacology: Clinical and Experimental},
  year={2001},
  volume={16}
}
The challenge in developing hypnotic agents for the treatment of insomnia is to balance the sedative effect needed at bedtime with the residual sedation on awakening. Zaleplon is a novel pyrazolopyrimidine hypnotic agent that acts as a selective agonist to the brain omega1 receptor situated on the alpha1 subunit of the GABAA receptor complex. Zaleplon was proven to be an effective hypnotic drug as it consistently and significantly reduced latency to persistent sleep in insomniac patients for… 
Comparative Pharmacokinetics and Pharmacodynamics of Short-Acting Hypnosedatives
  • D. Drover
  • Medicine
    Clinical pharmacokinetics
  • 2004
TLDR
While zaleplon may be best indicated for the delayed onset of sleep, zolpidem and zopiclone may be better indicated for maintaining a complete night’s sleep.
Pharmacokinetic Determinants of the Clinical Effects of Benzodiazepine Agonist Hypnotics
TLDR
O Ongoing pharmaceutical research has the objective of developing drug delivery innovations that can optimize hypnotic drug action by regulation of release and systemic exposure to short half-life BZ agonists.
Forensic Aspects of Hypnotic Drugs
TLDR
Overall, the non-benzodiazepine hypnotics have a good safety record but professionals involved in healthcare and forensics should be aware of the potential adverse effects.
Low-dose doxepin (3 and 6 mg) for the treatment of insomnia
TLDR
Low-dose doxepin offers a unique combination of potency and selectivity for H1, which may prove advantageous in the treatment of insomnia and the potential role of this compound in clinical practice is discussed.
Pharmacokinetics, pharmacodynamics and the pharmacokinetic/ pharmacodynamic relationship of zolpidem in healthy subjects
TLDR
Zolpidem reduced saccadic peak velocity, adaptive tracking performance, electroencephalogram (EEG) alpha power and visual analogue scale (VAS) alertness score and increased body sway, EEG beta power and VAS ‘feeling high’ and central nervous system effects normalised more rapidly than the decrease of plasma concentrations.
Treating insomnia: Current and investigational pharmacological approaches.
TLDR
The non-benzodiazepine compounds generally represent an improvement over benzodiazepines as a result of improved binding selectivity and pharmacokinetic profiles, however, the enduring potential for amnestic effects, next day residual sedation, and abuse and physical dependence, particularly at higher doses, underscores the need for new treatment strategies.
Pharmacotherapy for insomnia.
TLDR
The available efficacy data support the use of benzodiazepine receptor agonists (BzRAs), and to a lesser extent ramelteon, for the pharmacological treatment of insomnia.
Role of Zolpidem in the Management of Insomnia
TLDR
Zolpidem is an imidazo‐pyridine compound that enhances the GABAA receptor function by interaction with Omega‐1 receptor subtype that has rapid onset of action, improves total sleep duration, and reduces night‐time awakenings.
Review of the histamine system and the clinical effects of H1 antagonists: basis for a new model for understanding the effects of insomnia medications.
TLDR
This review was prompted by new studies of a selective H1 antagonist, which provide the first indication of the effects that are specifically associated with H1 antagonism, and hypothesize that significant sleep enhancing effects are likely when the histamine system is relatively active and the activity in other parallel wake promoting systems is relatively minimal.
Newer hypnotic drugs for the short-term management of insomnia: a systematic review and economic evaluation.
TLDR
The systematic review provided in this report suggests that an agnostic approach to cost-effectiveness is required for the use of hypnotic drugs for insomnia and it is suggested that further consideration should be given to a formal trial to allow head-to-head comparison of some of the key drugs in a double-blind RCT lasting at least 2 weeks, and of sufficient size to draw reasonable conclusions.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 124 REFERENCES
Zolpidem. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential.
TLDR
While zolpidem aids sedation, and may reduce memory or psychomotor function within the first 2 hours after administration of single oral doses, its use as a surgical premedicant remains to be established.
Zopiclone. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy as an hypnotic.
TLDR
Zopiclone is a useful alternative to other hypnotics, especially in patients intolerant of residual effects the morning after taking an hypnotic, which has a short half-life of about 5 hours and no long acting metabolites.
Comparison of the pharmacological profiles of the hypnotic drugs, zaleplon and zolpidem.
TLDR
The results show that zaleplon and zolpidem have similar pharmacological profiles, presumably related to their BZ1 (omega 1) receptor selectivity, however, the difference between doses producing motor deficits and those giving rise to other effects was greater for zolPidem than for zalplon.
Zopiclone. A review of its pharmacological properties and therapeutic efficacy as an hypnotic.
TLDR
Zopiclone is a well established alternative to the benzodiazepine hypnotics and may be particularly beneficial in those patients unable or unwilling to tolerate the residual effects associated with many other hypnotic agents.
Zaleplon: a review of its use in the treatment of insomnia.
TLDR
Zaleplon 5, 10 and 20 mg administered at bedtime, or later if patients have difficulty sleeping, is an effective and well tolerated hypnotic agent and represents a useful option in the management of patients with insomnia who have difficulties initiating sleep.
Zaleplon and triazolam in humans: acute behavioral effects and abuse potential
TLDR
Despite its non-benzodiazepine structure and unique benzodiazepin-receptor binding profile, the behavioral pharmacological profile of zaleplon is similar to that of triazolam, according to this double-blind, crossover study.
Clinical Pharmacokinetics and Pharmacodynamics of Zolpidem
TLDR
Zolpidem is a strong sedative with only minor anxiolytic, myorelaxant and anticonvulsant properties, and has been shown to be effective in inducing and maintaining sleep in adults.
Zopiclone. An update of its pharmacology, clinical efficacy and tolerability in the treatment of insomnia.
TLDR
Although the available data on rebound insomnia and dependence liability are encouraging, potential differences between zopiclone and the benzodiazepines in these respects may have little clinical relevance in the context of short term intermittent use of hypnotics, as it currently recommended.
Zolpidem: an update of its pharmacology, therapeutic efficacy and tolerability in the treatment of insomnia.
TLDR
Although zolpidem produced some psychomotor and memory impairment over the first few hours after administration, it had few next-day effects and was comparable or superior to flunitrazepam and flurazep am and comparable to other benzodiazepines in patients with insomnia.
Sleep latency is shortened during 4 weeks of treatment with zaleplon, a novel nonbenzodiazepine hypnotic. Zaleplon Clinical Study Group.
TLDR
Zaleplon appears to provide a favorable safety profile, as indicated by the absence of rebound insomnia and withdrawal symptoms once treatment was discontinued, and was effective in the treatment of insomnia in outpatients with DSM-III-R insomnia.
...
1
2
3
4
5
...